<code id='87CFF5504D'></code><style id='87CFF5504D'></style>
    • <acronym id='87CFF5504D'></acronym>
      <center id='87CFF5504D'><center id='87CFF5504D'><tfoot id='87CFF5504D'></tfoot></center><abbr id='87CFF5504D'><dir id='87CFF5504D'><tfoot id='87CFF5504D'></tfoot><noframes id='87CFF5504D'>

    • <optgroup id='87CFF5504D'><strike id='87CFF5504D'><sup id='87CFF5504D'></sup></strike><code id='87CFF5504D'></code></optgroup>
        1. <b id='87CFF5504D'><label id='87CFF5504D'><select id='87CFF5504D'><dt id='87CFF5504D'><span id='87CFF5504D'></span></dt></select></label></b><u id='87CFF5504D'></u>
          <i id='87CFF5504D'><strike id='87CFF5504D'><tt id='87CFF5504D'><pre id='87CFF5504D'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:3
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          In early work, researchers turn to CRISPR to treat Alzheimer's
          In early work, researchers turn to CRISPR to treat Alzheimer's

          AdobeWhenthegenome-editingtoolCRISPRisthoughtofasapotentialmedicine,thetargetsthatfirstcometomindare

          read more
          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more

          Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

          DarronCummings/APThebenefitsandrisksofEliLilly’streatmentforAlzheimer’sdiseasewereconfirmedindetaile